TransCode Therapeutics, Inc.
$5.93 -$1.32 (-18.21%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 20
A material event was filed (Form 8-K).
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 17
A material event was filed (Form 8-K).
8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 9
The stock moved +21.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 9 -
Jul 1
The stock moved +23.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 1 -
Jun 25
From its Feb 9 high, the share price fell 58%.
Peak close $10.72 on Feb 9; trough close $4.55 on Jun 25. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -58%
The story updates itself as events post · The wolf reports; you decide
Snapshot
About TransCode Therapeutics, Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.